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Background/aim: Obesity, diabetes mellitus, and metabolic syndrome (MetS) are associated with increased accumulated skin advanced
glycation end products. We aimed to evaluate the association of MetS components with skin autofluorescence (SAF) in patients with
morbid obesity.
Material and methods: Eight hundred and one patients with morbid obesity and 94 age-matched controls with normal body mass
index (BMI) and normal glucose metabolism were included. Advanced glycation end products (AGEs) were measured using SAF in the
forearm, with an AGE reader.
Results: The prevalence of MetS in patients with morbid obesity was 65.5% (n = 525). Type 2 diabetes mellitus (type 2 DM) and
hypertension were present in 40.9% (n = 328) and 43.7% (n = 357). Patients with morbid obesity and those with MetS had higher SAF
measurements compared with the control group, 1.85 ± 0.44 arbitrary unit (AU) and 1.86 ± 0.43 AU vs. 1.72 ± 0.30 AU, respectively (p =
0.016). There was no difference in SAF levels between patients with and without MetS. SAF measurements of patients without MetS were
not statistically different from the control group (p = 0.076). Patients with five MetS criteria had higher SAF measurements compared
with patients with fewer MetS components (p = 0.019). There was no difference in SAF levels between patients with type 2 DM, impaired
glucose metabolism, and patients with normal glucose metabolism (p = 0.513).
Conclusion: Although MetS and type 2 DM are known as factors related to increased SAF levels, obesity can cause elevated SAF
measurements in different ways independent of concomitant comorbid diseases. Larger studies with longer follow-ups are needed to
enlighten the underlying mechanism.
Key words: Advanced glycation end products, metabolic syndrome, morbid obesity, skin autofluorescence

1. Introduction
Obesity is a component of metabolic syndrome (MetS)
or predisposes to MetS [1], which constitutes several
cardiovascular risk factors, including insulin resistance,
abdominal obesity, atherogenic dyslipidemia, and
hypertension, and its prevalence has been increasing due
to the growing epidemic of obesity and type 2 diabetes
mellitus (type 2 DM) [2]. Although patients with obesity
are predisposed to MetS, it does not develop in all patients
with obesity [1].
The obesity-related impaired endothelial function has
been reported in previous reports, which was evaluated
via measurement of carotid intima-media thickness, flowmediated endothelial-dependent vasodilation, advanced
glycation end products (AGEs), the receptor of AGEs,
and skin autofluorescence (SAF) [3–6]. AGEs are glycated
proteins, lipids, and nucleic acids that present with chronic
exposure to hyperglycemia, inflammation, and oxidative

stress [3, 7]. AGEs are considered a marker of metabolic
memory [5, 8]. AGEs can accumulate in tissues through
aging, dietary intake, and smoking. Studies over the last
decade have revealed a progressive role of AGEs in the
development of type 2 DM, cardiovascular disease (CVD),
hypertension, and other chronic diseases [9, 10].
Measurement of skin AGE accumulation using
autofluorescence correlates with the AGEs in skin biopsies
such as pentosidine, carboxymethyl lysine (CML),
and carboxyethyl lysine (CEL) [7,10]. The relationship
between micro-macrovascular complications and skin
autofluorescence in patients with diabetes mellitus,
renal failure, and cardiac diseases has been previously
investigated [8,9,11,12], and SAF is an independent
predictor of long-term cardiovascular complications.
However, limited studies reported AGEs levels [13–15]
or SAF [5, 16] in patients with obesity. Body mass index
(BMI) was found to be inversely correlated with SAF in
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patients with obesity [5]. Increased AGEs and decreased
soluble AGE receptors were detected in patients with
obesity [5,17,18].
In previous reports [3,19], patients with MetS had
higher SAF measurements compared with subjects without
MetS. Also as the components of MetS increased, elevated
SAF values were detected [19]. The decreased soluble form
of receptor for advanced glycation end products (sRAGE)
[20] and increased serum AGEs [13] were also found to
be correlated with the increasing number of components
of MetS.
We hypothesized that the increased number of MetS
components and the presence of type 2 DM could impair
SAF measurements in patients with morbid obesity. In this
study, we aimed to evaluate the association of MetS and
its components with SAF in patients with morbid obesity
and to examine whether type 2 DM or other components
of MetS contributed to the increase in SAF in patients with
obesity.
2. Methods
2.1. Patient’s characteristics
The data of 801 patients with morbid obesity who
were volunteered for the SAF measurements during
their follow-up at Marmara University Medical School
Endocrinology and Metabolism Department outpatient
clinic were examined retrospectively. The laboratory data
[fasting plasma glucose, glycated hemoglobin (HbA1c),
serum low-density lipoprotein cholesterol (LDL-c), highdensity lipoprotein cholesterol (HDL-c), triglyceride,
total cholesterol, creatinine] were obtained from the
medical records. Patients with acute infectious and
chronic inflammatory diseases, chronic kidney disease,
exogenous glucocorticoid intake, concomitant alcoholism,
and active smokers were excluded from the study. The
classification of obesity was made using the body mass
index (BMI)-dependent obesity staging of the World
Health Organization (WHO). Morbid obesity was defined
as a BMI over 40 kg/m2.
SAF measurements of 94 age-matched controls with
normal BMI and normal glucose levels were examined
cross-sectionally and included in the analysis. None of
the control subjects had type 2 DM, hypertension, chronic
renal disease, acute infectious, and chronic inflammatory
diseases. All control subjects had BMI values below 30 kg/
m2.
The study protocol was approved by the local ethics
committee (09.2020.1122) and was conducted following
the ethical principles stated in the Declaration of Helsinki.
2.1.1. Physical measurements and laboratory evaluation
Clinical, demographic parameters (age, sex), and medical
history were recorded from medical records. Height,
weight, BMI, waist circumference (WC), and systolic
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and diastolic blood pressures were measured. BMI was
calculated by dividing the weight in kg by the square of the
height in m (kg/m2). Standing height was measured using
a stadiometer nearest 0.5 cm without shoes. Bodyweight
was measured using a digital electronic scale to the nearest
0.1 kg. WC was measured in the standing position in the
middle of the iliac crest and the lower costal margin to
the nearest 0.5 cm. Systolic and diastolic blood pressure
were measured 10 min after resting in the supine position
using an automated Dinamap Monitor (GE Healthcare,
Freiburg, Germany).
Fasting glucose level was measured using an
enzymatic ultraviolet (UV) test (hexokinase method);
total cholesterol, HDL-c, and triglycerides were analyzed
using an enzymatic color method on an AU5800 analyzer
(Beckman Coulter, USA). Creatinine levels were analyzed
using a kinetic color test (Jaffé method) with an AU5800
analyzer (Beckman Coulter, USA). HbA1c was analyzed
using a boronate affinity chemistry with high-performance
liquid chromatography on a Premier Hb9210 (Trinity
Biotech, USA).
2.2. Skin autofluorescence evaluation
AGEs were measured using SAF in the forearm
approximately 10 cm below the elbow fold, with an AGE
Reader (DiagnOptics Technologies, Groningen, The
Netherlands) at room temperature in a semidark room
(Figure). Autofluorescence measurements were performed
according to previous protocols [7, 21]. In brief, the AGE
reader brightens approximately 4 cm2 skin surface with a
300 and 420 nm (peak intensity at ~ 370 nm) wavelength,
and the light emitted and reflected from the skin is
measured with an internal spectrometer in the range of
300–600 nm. SAF was calculated as the ratio between

Figure. The image of the AGE reader used in the evaluation of
skin autofluorescence.
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average emitted light intensity (420–600 nm) and the
average excited light intensity (range, 300–420 nm) and
multiplied by 100 and were presented as arbitrary units
(AU). The SAF measurement was conducted three times,
and the mean of the values was accepted as the target
value.
2.3. Definition of metabolic syndrome and diabetes
mellitus
MetS was deﬁned according to the revised National
Cholesterol Education Program-Adult Treatment Panel
(NCEP-ATP) III criteria [22]. MetS present if three or
more of the following five criteria were met: (1) WC over
102 cm for men and over 88 cm for women; (2) fasting
triglyceride levels over 150 mg/dL or pharmacologic
treatment for high triglyceride levels; (3) fasting HDL-c
levels less than 50 mg/dL in women and less than 40 mg/
dL in men or pharmacologic treatment for low HDL-c
levels; (4) blood pressure over 130/85 mm Hg or using
antihypertensive treatment; (5) fasting plasma glucose
(FPG) of 100 mg/dL and higher or receiving treatment for
high blood sugar, but HbA1c less than 6.5%. Patients with
a previous history of type 2 DM or newly diagnosed type
2 DM were excluded from the MetS group.
Diagnosis of diabetes mellitus and prediabetes were
made according to the American Diabetes Association
(ADA) 2017 guidelines [23]. Subjects with FPG levels of
100–125 mg/dL but 2-h postprandial glucose levels below
140 mg/dL were defined as impaired fasting glucose (IFG).
Subjects with 2-h postprandial glucose levels of 140–199
mg/dL but FPG levels below 100 mg/dL were defined as
isolated impaired glucose tolerance (IGT), and subjects
with FPG levels of 100–125 mg/dL and 2-h postprandial
glucose levels of 140–199 mg/dL was defined as combined
prediabetes (IFG+IGT).
2.4. Statistical analysis
Continuous variables are summarized using descriptive
statistics presented as mean and standard deviation (SD).
Categorical variables are summarized using counts and
percentages. Categorical data were analyzed using the
chi-square (χ2) test or Fisher’s exact test as appropriate.
Student’s t-test and analysis of variance (ANOVA) were
used for parametric variables. ANOVA analysis was
performed to compare subjects with MetS, without MetS,
and control group. After then post hoc Tukey’s test was
performed to compare patients with MetS, without MetS.
In addition, to compare parameters of patients with type 2
DM, patients without DM with MetS, and patients without
DM without MetS first ANOVA analyses were performed.
Pearson’s correlation analysis was used to define the
relationship between SAF and clinical (age, BMI, WC,
systolic and diastolic blood pressure) and biochemical
parameters (FPG, 2-h postprandial glucose level, HbA1c,
total cholesterol, HDL-c, LDL-c, and triglycerides).

Multiple regression analysis was performed to define
the predictors of SAF. Predictors with a possible influence
on dependent variables were added as covariates (age,
BMI, systolic blood pressure, HbA1c, LDL-c, and
triglycerides).
The results were evaluated at a 95% confidence
interval, and p < 0.05 was considered statistically
significant. All statistical analyses were performed using
software (GraphPad InStat 3.0; GraphPad Software, Inc.,
San Diego, CA, USA).
3. Results
3.1. General characteristics of the patients
A female preponderance [F/M: 633/168] with a mean age
of 43.8 ± 10.4 years was observed. While the mean age
of female subjects was 44 ± 10.5 years, it was 43.7 ± 10.4
years in males. The mean BMI was 47.8 ± 7.4 kg/m2 and
47.9 ± 7.9 kg/m2 in female and male patients, respectively.
Type 2 DM and hypertension were observed in 40.9% (n
= 328), 43.7% (n = 357) of the patients, respectively. The
prevalence of MetS was 65.5% (n = 525), 79% (n = 416)
of them was female and 21% (n = 109) was male subjects.
On the other hand, 78.6% (217) of the 276 subjects
without MetS were female and 21.4% (59) male. Clinical
characteristics and laboratory parameters are shown in
Table 1. Statistically significant differences between obese
patients and the control group were detected in FPG,
HbA1c, triglyceride, LDL-c, HDL-c, and total cholesterol
levels (p < 0.001).
3.2. Skin autofluorescence evaluation according to the
presence of MetS
When patients with obesity were divided into two
subgroups as patients with and without MetS, there was a
significant difference in systolic (p < 0.001) and diastolic
blood pressure (p = 0.001), FPG (p < 0.001), HbA1c (p
= 0.001), total cholesterol (p = 0.007), triglyceride (p =
0.019), but SAF measurements did not differ according
to the presence of MetS (p = 0.091). By contrast, patients
with MetS had higher SAF measurements than the control
group (p = 0.034), but the SAF measurements of patients
without MetS were not statistically different from the
control group (p = 0.076).
When patients were grouped according to the number
of MetS components, there were 86 (10.7%) patients with
one criterion, 190 (23.7%) patients with two criteria,
301 (37.6%) patients with three criteria, 172 (21.5%)
patients with four criteria, and 52 (6.5%) patients with
five criteria. The levels of SAF according to the number of
MetS components were as follows: 1.86 ± 0.37 AU, 1.78 ±
0.35 AU, 1.83 ± 0.42 AU, 1.87 ± 0.48 AU, and 2.09 ± 0.59
AU, respectively. Although patients with five components
of MetS had higher SAF levels (p = 0.019), there was no
statistical difference between the other groups.
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Table 1. Clinical characteristics and laboratory findings of the patients with obesity and control group.
Parameter

All
n = 801

MetS +
n = 525

MetS n = 276

Control
n = 94

p

Age (years)

43.8 ± 10.4

45.6 ± 10.4

40.5 ± 9.7

44.0 ± 11.0

<0.001

Sex (F/M)

633/168

416/109

217/59

66/28

0.640

DM, n (%)

328 (40.9)

286 (54.5)

42 (15.2)

0 (0)

<0.001¥

Hypertension, n (%)

350 (43.7)

300 (57.1)

50 (18.1)

0 (0)

<0.001ª

BMI (kg/m2)

47.8 ± 7.4

48.1 ± 7.5

46.8 ± 7.1

24.7 ± 3.4

<0.001

Weight (kg)

127.6 ± 22.3

128.4 ± 22.1

126.1 ± 22.7

67.4 ± 11.1

<0.001

WC of women (cm)

127.2 ± 14.2

127.9 ± 14.9

125.7 ± 12.8

86.8 ± 9.7

<0.001

WC of men (cm)

134.9 ± 15.3

136.5 ± 14.4

131.3 ± 16.9

88.3 ± 6.5

<0.001

SBP (mmHg)

128.5 ± 20.8

131.8 ± 21.3

121.9 ± 18.0

108.7 ± 12.5

<0.001γ

DBP (mmHg)

78.7 ± 14.8

80.0 ± 15.6

76.0 ± 12.7

66.2 ± 9.4

<0.001δ

FPG (mg/dL)

96.5 ± 26.4

98.7 ± 26.1

92.8 ± 26.6

90.9 ± 18.6

<0.001ß

HbA1c (%)

6.0 ± 1.5

6.1 ± 1.6

5.8 ± 1.2

5.0 ± 0.6

<0.001§

Triglycerides (mg/dL)

160.7 ± 89.6

167.0 ± 97.9

148.2 ± 68.6

98.5 ± 75.2

<0.001

HDL-c (mg/dL)

46.6 ± 10.3

46.7 ± 10.2

46.3 ± 10.4

53.7 ± 14.1

<0.001#

LDL-c (mg/dL)

130.3 ± 40.2

132.2 ± 42.6

126.7 ± 35.0

115.7 ± 37.3

0.003

SAF (AU)

1.85 ± 0.44

1.87 ± 0.46

1.81 ± 0.38

1.72 ± 0.30

0.016*

Values reported as mean ± standard deviation.
BMI, Body mass index; DBP, diastolic blood pressure; DM, type 2 diabetes mellitus; F, female; FPG, fasting plasma
glucose (65–100 mg/dL); HDL, high-density cholesterol (35–70 mg/dL); LDL, low-density cholesterol (0–140 mg/dL);
M, male; MetS, metabolic syndrome; SAF, skin autofluorescence; SBP, systolic blood pressure; Total-C, total cholesterol
(30–200 mg/dL); triglycerides (30–200 mg/dL); WC, waist circumference.
¥
p < 0.001 for MetS+ vs. MetS-; ª p < 0.001 for MetS+ vs. MetS; γ p < 0.001 for MetS+ vs. MetS-; δ p = 0.001 for MetS+
vs. MetS-; ß p < 0.001 for MetS+ vs. MetS-; §p = 0.001 for MetS+ vs. MetS-; #p = 0.019 for MetS+ vs. MetS-. There was no
statistical significance among other parameters between MetS+ vs. MetS- groups.
*p = 0.091 for MetS+ vs. MetS-; p = 0.034 for MetS+ vs. control group; p = 0.076 for MetS- vs. control group

3.3. Skin autofluorescence evaluation according to
glucose metabolism
After excluding individuals with type 2 DM from
among patients with obesity, subjects without DM were
categorized into two subgroups as those with and without
MetS. The findings of patients were compared in three
groups; patients with type 2 DM, patients without DM with
MetS, and patients without DM without MetS. General
characteristics and biochemical parameters according to
these subgroup analyses are summarized in Table 2. In
patients with obesity, there was no statistical difference in
SAF measurements in patients with or without type 2 DM
(p = 0.272). After excluding patients with type 2 DM, there
was still no difference in SAF measurements in patients
without DM with MetS, and patients without DM without
MetS (p = 0.213).
When the patients were divided into three subgroups
as patients with type 2 DM (n = 328), impaired glucose
metabolism (n = 240), and normal glucose metabolism (n
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= 233), SAF measurements were found to be similar: 1.87
± 0.46 AU, 1.84 ± 0.45 AU, and 1.84 ± 0.40 AU (p = 0.513).
3.4. Correlation and multiple regression analyses
A weak positive correlation with SAF and systolic blood
pressure (r: 0.096, p = 0.009) was observed. There was no
significant correlation with SAF and other parameters (age,
BMI, WC, FPG, 2-h postprandial glucose level, HbA1c,
total cholesterol, HDL-c, LDL-c, and triglycerides) (Table
3).
Multiple regression analysis showed that SAF was
independently associated with systolic blood pressure (p =
0.023) and HbA1c (p < 0.001), but there were no association
between SAF and age, BMI, LDL-c, and triglycerides (R2 =
4.22%, p = 0.005) (Table 4).
4. Discussion
In this study, patients with morbid obesity and those with
MetS had higher SAF measurements than healthy controls.
However, they found no difference in SAF levels between
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Table 2. Clinical characteristics and laboratory findings of patients according to the presence of
diabetes mellitus and metabolic syndrome.
Parameter

DM
n = 328

MetS +
n = 239

MetS n = 234

p

Age (years)

46.9 ± 10.1

43.3 ± 9.9

39.8 ± 9.9

<0.001

Sex (F/M)

255/73

190/49

188/46

0.679

BMI (kg/m2)

48.3 ± 7.7

48.3 ± 7.6

46.4 ± 6.5

0.071

Weight (kg)

127.3 ± 23.1

129.5 ± 21.9

126.2 ± 21.5

0.401

WC of women (cm)

128.3 ± 12.0

127.3 ± 17.7

125.3 ± 12.9

0.071

WC of men (cm)

137.0 ± 11.7

137.7 ± 10.4

130.9 ± 17.6

0.121

SBP (mmHg)

130.5 ± 20.4

131.3 ± 22.2

122.5 ± 18.7

<0.001

DBP (mmHg)

79.1 ± 15.0

80.2 ± 15.8

76.3 ± 13.0

0.060

FPG (mg/dL)

113.9 ± 52.9

93.6 ± 13.2

88.2 ± 10.1

<0.001

HbA1c (%)

6.3 ± 1.4

5.4 ± 0.5

5.4 ± 0.4

<0.001

Triglycerides (mg/dL)

167.1 ± 83.5

159.6 ± 95.2

147.9 ± 67.4

0.033

HDL-c (mg/dL)

46.2 ± 10.8

47.2 ± 12.7

47.1 ± 10.3

0.261

LDL-c (mg/dL)

131.0 ± 37.9

132.6 ± 46.8

127.0 ± 35.9

0.348

SAF (AU)

1.85 ± 0.42

1.86 ± 0.43

1.82 ± 0.39

0.272*

Values reported as mean ± standard deviation.
BMI, Body mass index; DBP,diastolic blood pressure; DM, type 2 diabetes mellitus; F, female; FPG,
fasting plasma glucose (65–100mg/dL); HDL, high-density cholesterol (35–70 mg/dL); LDL, lowdensity cholesterol (0–140 mg/dL); M, male; MetS, metabolic syndrome; SAF, skin autofluorescence;
SBP, systolic blood pressure; Total-C, total cholesterol (30–200 mg/dL); triglycerides (30–200 mg/dL);
WC, waist circumference.
*p = 0.911 for DM+ vs. MetS+; p = 0.123 for DM+ vs. MetS-; p = 0.213 for MetS+ vs. MetSTable 3. Correlation analysis of parameters with skin
autofluorescence.
R

p value

Age (years)

0.041

0.263

BMI (kg/m )

0.029

0.420

WC

0.020

0.600

SBP (mmHg)

0.096

0.009

DBP (mmHg)

0.041

0.257

HbA1c (%)

0.039

0.299

Triglycerides (mg/dL)

0.037

0.302

HDL-c (mg/dL)

0.054

0.137

LDL-c (mg/dL)

0.014

0.700

2

BMI, Body mass index; DBP, diastolic blood pressure; HDL,
high-density cholesterol; LDL, low-density cholesterol; SBP,
systolic blood pressure; WC, waist circumference.

patients with and without MetS. There was no difference in
patients with obesity between SAF levels according to type
2 DM or impaired glucose metabolism. Although MetS and

type 2 DM are known as factors related to increased SAF
levels, obesity was related to elevated SAF measurements
independent of concomitant comorbidities.
Uribarri et al. study, which included subjects with
central obesity, reported that higher serum AGEs were
present in subjects with more than one MetS criterion
compared with subjects without MetS criteria [13]. In van
Waateringe et al. [19] and Den Engelsen et al.’s [3] studies,
higher SAF measurements were detected in subjects with
MetS compared with patients without MetS. Although
there was no difference in SAF measurements according
to the presence of MetS in our study, it could be detected
if more patients with morbid obesity without MetS were
included. However, due to the relatively fewer patients
with morbid obesity without MetS, it is difficult to increase
the number of these patients. In addition, previous studies
mostly included overweight subjects or patients with class
1 and rarely class 2 obesity, but we only evaluated patients
with morbid obesity, and these differences between patient
groups may be responsible for these divergent results.
Several previous reports, which evaluated serum AGEs,
showed that serum AGEs were not increased in individuals
with obesity without MetS characteristics [24,25]. On
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Table 4. Multiple regression analysis of parameters associated with skin autofluorescence.
Dependent variable

Independent
variable

Odds ratio
(%)

Standard
error

%95 CI

p value

Age (years)

1.090

0.062

1.001–1.007

0.313

BMI (kg/m )

0.301

0.005

0.995–1.007

0.519

SBP (mmHg)

0.413

0.002

1.003–1.004

0.023

HbA1c (%)

0.454

0.008

1.002–1.011

<0.001

Triglycerides (mg/dL)

0.560

0.001

1.001–1.026

0.957

LDL-c (mg/dL)

2.907

0.001

1.000–1.015

0.600

2

SAF

Pseudo R2

4.22%

BMI, Body mass index; LDL, low-density cholesterol; SAF, skin autofluorescence; SBP, systolic blood pressure

the other hand, van Waateringe et al.’s study showed that
patients with MetS had similar SAF levels whether obese or
not, and there was also no statistically significant difference
in SAF between individuals with and without obesity, but
patients with enlarged WC had higher SAF levels [19]. In
our study, there was no statistical difference in SAF levels
between patients with obesity without MetS and the control
group, but when all patients with obesity were compared
with nonobese subjects, SAF levels were found to be higher
in the obese group compared with controls, but SAF levels
did not differ in patients with or without MetS. Maybe we
can attribute this due to the presence of enlarged WC in all
our patients with obesity.
In Tanaka et al.’s study with patients with type 2 DM,
systolic blood pressure was related to SAF [26], and in van
Waateringe et al.’s study with subjects with MetS elevated
blood pressure was related to higher SAF [19]. In our study,
multivariate regression analysis showed that systolic blood
pressure explained 2.7% of SAF measurements, but no
other parameters were statistically significant.
Increased AGEs levels in the tissue and circulation are
well-established in patients with diabetes [9,11]. Although
we hypothesized that the presence of type 2 DM could
also affect SAF in patients with morbid obesity, there was
no difference in SAF measurement between patients with
and without type 2 DM with obesity. However, when we
compared patients with type 2 DM with the controls,
SAF was higher in patients with type 2 DM. In previous
reports, obesity-related subclinical atherosclerosis and
endothelial dysfunction [27] have been reported regardless
of concomitant diabetes and metabolic syndrome [28]. We
may attribute these findings to the effect of obesity itself.
Morbid obesity could be the main cause of increased SAF
levels rather than concomitant type 2 DM or MetS.
In Sprung et al.’s study, which used flow-mediated
dilatation (FMD) for the evaluation of endothelial
dysfunction, patients with MetS also had lower FMD
compared with patients without MetS, both in the obese
and nonobese group [29], and also an increased number of
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MetS components was found to be associated with a lower
FMD. He et al. showed a relationship between plasma
receptor of AGEs levels and MetS and its components in
adolescents with central obesity [20]. In van Waateringe
et al.’s study, as the components of MetS increased, higher
SAF levels were detected [19]. In our study, patients with
five components of MetS had higher SAF levels than other
groups.
The major limitation of this study is the lack of diet,
smoking, and exercise history, which can influence AGEs
levels and SAF measurements. Also, this study is performed
retrospectively, which makes it difficult to understand the
reasons for the changes in SAF levels. To define causality
in the relationship between SAF levels and morbid obesity,
type 2 DM, and MetS, long-term follow-up studies
including serum AGEs, and SAF measurements with the
evaluation of a diet diary and smoking habits are needed.
In conclusion, this study showed that morbid obesity
was the main cause of increased SAF levels rather than
concomitant type 2 DM or MetS. Although MetS and type
2 DM are known as factors related to increased SAF, obesity
can cause elevated SAF measurements in different ways
independent of concomitant comorbid diseases. Larger
studies with longer follow-up are needed to enlighten the
underlying mechanism.
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